Need Public Policy for Human Gene Editing, Heatwaves, or Asteroids? Try Thinking Like a Citizen
By Nicholas Weller, Michelle Sullivan Govani, Mahmud Farooque,
Issues in Science and Technology
| 05. 19. 2021
In a ballroom at the Arizona Science Center one afternoon in 2017, more than 70 Phoenix residents—students, teachers, nurses, and retirees—gathered around tables to participate in a public forum about how cities can respond to extreme weather such as heat waves. Each table was covered in colorful printouts with a large laminated poster resembling a board game. Milling between the tables were decisionmakers from local government and the state. All were taking part in a deliberative process called participatory technology assessment, or pTA, designed to break down the walls between “experts” and citizens to gain insights into public policy dilemmas involving science, technology, and uncertainty.
Foreshadowing their varied viewpoints and experiences, participants prepared differently for the “extreme weather” of the heavily air conditioned ballroom, with some gripping cardigans around their shoulders while others were comfortable in tank tops. Extreme heat is something all the participants were familiar with—Phoenix is one of the hottest cities in the country—but not everyone understood the unequal way that heat and related deaths affect different parts of the Valley of the Sun. Though a...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...